Based on this evaluation, we analyzed the expression of nine additional genes—ASH1L, ITGB8, PLCB1, VAMP3, RARG, NR2F6, CFL2, LRRC32, and MRFAP1—using the BIOSTORM HCC cohort data, comparing sorafenib responders versus non-responders. Here, PLCB1 is linked to hepatocellular carcinoma.